Feme ka ho toba 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2

Hangata re nahana le ho itloaetsa ho lumellana le phetoho ea maemo a hau, 'me re hole.Re ikemiselitse ho fihlela katleho ea kelello le 'mele e ruileng hammoho le bophelo ba feme ka ho toba 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Sepheo sa rona e tla ba ho thusa bareki ho tseba sepheo sa bona. .Re ntse re etsa matsapa a matle a ho fihlela boemo bona ba win-win mme re u amohela ka tieo hore u ingolise bakeng sa rona.
Hangata re nahana le ho itloaetsa ho lumellana le phetoho ea maemo a hau, 'me re hole.Re ikemiselitse ho fihlela katleho ea kelello le 'mele e ruileng hammoho le ba phelang bakeng saChina 4-Dibuthylamino-2-Hydroxybenzophenone le Bba, Ho ba teng ha rona khafetsa ha lihlahisoa tsa boemo bo holimo le litharollo hammoho le ts'ebeletso ea rona e ntlehali ea pele ho thekiso le ka mor'a thekiso ho netefatsa tlholisano e matla 'marakeng o ntseng o eketseha oa lefatše.amohela bareki ba bacha le ba khale ba tsoang mekhoeng eohle ea bophelo ho ikopanya le rona bakeng sa likamano tsa nako e tlang tsa khoebo le katleho e kopaneng!

2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid e sebelisoa e le bohareng ba Eltrombopag.
Eltrombopag, e ntlafalitsoeng ke GlaxoSmithKline (GSK) naheng ea UK, 'me hamorao e ile ea ntlafatsoa ka kopanelo le Novartis naheng ea Switzerland, ke molek'hule oa pele o amohetsoeng oa molek'hule o se nang peptide TPO receptor agonist lefatšeng.Eltrombopag e amohetsoe ke US FDA ka 2008 bakeng sa kalafo ea idiopathic thrombocytopenic purpura (ITP), le ka 2014 bakeng sa kalafo ea anemia e matla ea aplastic (AA).Hape ke moriana oa pele o amohetsoeng ke US FDA bakeng sa kalafo ea AA lilemong tse 30 tsa morao tjena.
Ka December 2012, US FDA e ile ea amohela Eltrombopag bakeng sa phekolo ea thrombocytopenia ho bakuli ba nang le lefu la sebete le sa foleng la C (CHC), e le hore bakuli ba hepatitis C ba nang le bokooa bo bobe ka lebaka la palo e tlaase ea platelet ba ka qala le ho boloka phekolo e tloaelehileng ea interferon bakeng sa mafu a sebete.Ka February 3, 2014, GlaxoSmithKline e phatlalalitse hore FDA e fane ka katleho ea meriana ea phekolo ea Eltrombopag bakeng sa phekolo ea hemopenia ho bakuli ba nang le lik'hemik'hale tse matla tsa aplastic anemia (SAA) tse sa kang tsa arabela ka botlalo ho immunotherapy.Ka August 24, 2015, US FDA e amohetse Eltrombopag bakeng sa phekolo ea thrombocytopenia ho batho ba baholo le bana ba lilemo li 1 ho ea holimo ba nang le lefu le sa foleng la immune thrombocytopenia (ITP) ba nang le karabelo e sa lekaneng ho corticosteroids, immunoglobulins kapa splenectomy.Ka January4, 2018, Eltrombopag e ile ea amoheloa hore e ngolisoe Chaena bakeng sa phekolo ea "immune immune thrombocytopenia" (ITP).

Hangata re nahana le ho itloaetsa ho lumellana le phetoho ea maemo a hau, 'me re hole.Re ikemiselitse ho fihlela katleho ea kelello le 'mele e ruileng hammoho le bophelo ba feme ka ho toba 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Sepheo sa rona e tla ba ho thusa bareki ho tseba sepheo sa bona. .Re ntse re etsa matsapa a matle a ho fihlela boemo bona ba win-win mme re u amohela ka tieo hore u ingolise bakeng sa rona.
Feme ka ho tobaChina 4-Dibuthylamino-2-Hydroxybenzophenone le Bba, Ho ba teng ha rona khafetsa ha lihlahisoa tsa boemo bo holimo le litharollo hammoho le ts'ebeletso ea rona e ntlehali ea pele ho thekiso le ka mor'a thekiso ho netefatsa tlholisano e matla 'marakeng o ntseng o eketseha oa lefatše.amohela bareki ba bacha le ba khale ba tsoang mekhoeng eohle ea bophelo ho ikopanya le rona bakeng sa likamano tsa nako e tlang tsa khoebo le katleho e kopaneng!